Blood Dyscrasias Induced by Psychotropic Drugs
The DOI matches its Crossref record.
Abstract
Drugs can cause a variety of blood dyscrasias, e. g., by interfering with hematopoiesis in the bone marrow or damaging mature blood cells by antibodies. Although numerous reports on the risks of adverse hematological effects associated with psychotropic drugs have led to stringent monitoring requirements for some compounds, particularly neuroleptics, it is still difficult to estimate the true prevalence of such risks. Sixteen episodes of thrombocytopenia, 63 of neutropenia, 22 of agranulocytosis, 4 episodes of severe neutro- and thrombocytopenia, and 2 of pancytopenia were documented by the drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) in a population of 122,562 patients between 1993 and 2000. All cases were related to the epidemiological data provided for this population and systematically analyzed as regards history of medication, co-medication, and the clinical course. Putative risk rates for the main groups of medications and a number of drugs could be estimated with this database. Most changes in the white blood cell counts, which were rated as probably or definitely drug-induced, were attributed to clozapine (0.18 % of patients exposed), carbamazepine (0.14 %) and perazine (0.09 %). In patients on newer atypical neuroleptics, we documented neutropenia assumed to be probably or definitely drug-related in five patients during treatment with olanzapine and in one case with risperidone. In all five olanzapine-related cases, the drugs were the sole cause of the adverse drug reactions. All surveyed patients who received clozapine showed no difference in age and gender distribution from those who developed hematological changes. Incidences of hematological changes for antidepressants were much lower (about 0.01 %). Although the methodological accuracy of these findings has to be critically discussed these data could be of considerable clinical relevance and should be helpful in making clinical treatment decisions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clozapine carries the greatest risk for drug‐induced changes in white blood cell counts, with approximately 0.18% of patients experiencing changes rated as probably or definitely drug induced.828”
In the citing paper
“Carbamazepine may be a risk factor for leucopenia,828, 829, 830 although this finding is not robust.831”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Haematological toxicity of drugs used in psychiatry
Flanagan, R. J., & Dunk, L. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.917 · Cited by 236
Ng, F., Mammen, O. K., Wilting, I., Sachs, G. S., Ferrier, I. N., Cassidy, F., Beaulieu, S., Yatham, L. N., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00737.x · Cited by 192
Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
Seeman, M. V. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn023 · Cited by 186
Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 184
Cancer diagnosis in people with severe mental illness: practical and ethical issues
Howard, L. M., Barley, E. A., Davies, E., Rigg, A., Lempp, H., Rose, D., Taylor, D., & Thornicroft, G. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70085-1 · Cited by 177
Clozapine-induced agranulocytosis
Mijovic, A., & MacCabe, J. H. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04215-y · Cited by 157
Mena, M. A., & de Yébenes, J. G. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.6.759 · Cited by 145
Steiner, J., Frodl, T., Schiltz, K., Dobrowolny, H., Jacobs, R., Fernandes, B. S., Guest, P. C., Meyer-Lotz, G., Borucki, K., Bahn, S., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz068 · Cited by 123
Sex-Specific Differences in Side Effects of Psychotropic Drugs: Genes or Gender?
Haack, S., Seeringer, A., Thürmann, P. A., Becker, T., & Kirchheiner, J. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.102 · Cited by 101
Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., & Dodd, S. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.4.731 · Cited by 79
Pharmacotherapy challenges in patients with first-episode psychosis
Abdel‐Baki, A., Ouellet‐Plamondon, C., & MALLA, A. K. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.029 · Cited by 70
Sodium valproate and clozapine induced neutropenia: A case control study using register data
Malik, S., Lally, J., Ajnakina, O., Pritchard, M., Krivoy, A., Gaughran, F., Shetty, H., Flanagan, R. J., & MacCabe, J. H. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.041 · Cited by 69
Rechallenging With Clozapine Following Neutropenia: Treatment Options for Refractory Schizophrenia
Ghaznavi, S., Nakic, M., Rao, P., Hu, J., Brewer, J. A., Hannestad, J. O., & Bhagwagar, Z. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111823 · Cited by 68
Monitoring the Safe Use of Clozapine: A Consensus View from Victoria, Australia
Berk, M., Fitzsimons, J., Lambert, T., Pantelis, C., Kulkarni, J., Castle, D. J., Ryan, E. W., Jespersen, S., McGorry, P. D., Berger, G. E., et al. (2007) · CNS Drugs · doi:10.2165/00023210-200721020-00003 · Cited by 64
Clozapine-Induced Agranulocytosis and its Genetic Determinants
Opgen‐Rhein, C., & Dettling, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1101 · Cited by 57
Current schizophrenia drugs: efficacy and side effects
Krebs, M., Leopold, K., Hinzpeter, A., & Schaefer, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1005 · Cited by 50
Hart, X. M., Gründer, G., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Cumming, P. D., Frajerman, A., Hefner, G., Howes, O. D., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2366235 · Cited by 42
Fabrazzo, M., Prisco, V., Sampogna, G., Perris, F., Catapano, F., Monteleone, A. M., & Maj, M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.06.068 · Cited by 38
Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia
Montgomery, J. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.08.005 · Cited by 31
Are clozapine blood dyscrasias associated with concomitant medications?
Demler, T. L., & Trigoboff, E. (2011) · PubMed · Cited by 29
Sikich, L., & Maloney (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6614 · Cited by 26
Yang, C.-C., Wang, X., Chou, P., & Lin, C. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04659-2 · Cited by 25
Mathewson, K. A., & Lindenmayer, J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a583b · Cited by 24
Glocker, C., Grohmann, R., Burkhardt, G., Seifert, J., Bleich, S., Held, T., Toto, S., Stübner, S., & Schüle, C. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02589-7 · Cited by 23
Self-citationPsychopharmacologic Treatment of Schizophrenia in Adolescents and Children
Lee, E. S., Kronsberg, H., & Findling, R. L. (2019) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.08.009 · Cited by 23
Filia, S., Wheelhouse, A., Lee, S. J., Main, M., de Castella, A. R., Wilkins, S., & Kulkarni, J. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867411433210 · Cited by 23
Héquet, O., Bourgeot, J.-P., Michallet, M., Morélon, E., Dubernard, J., Dubois, V., & Devauchelle, B. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.23 · Cited by 23
Reversible Neutropenia during Treatment with Olanzapine: Three Case Reports
Cordes, J., Streit, M., Loeffler, S., von Wilmsdorff, M., Agelink, M. W., & Klimke, A. (2004) · The World Journal of Biological Psychiatry · doi:10.1080/15622970410029938 · Cited by 21
Careful Monitoring for Agranulocytosis During Carbamazepine Treatment
Daughton, J., Padala, P. R., & Gabel, T. L. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0510a · Cited by 20
Clozapine reinitiation following a "red result" secondary to chemotherapy
Munshi, T. A., Hassan, T., & Mazhar, N. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49028 · Cited by 18
Mirtazapine-Induced Nightmares
Mathews, M., Basil, B., Evcimen, H., Adetunji, B., & Joseph, S. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0510b · Cited by 17
Oloyede, E., Bachmann, C., Dzahini, O., Alcaraz, J. M. L., Singh, S. D., Vallianatu, K., Funk, B., Whiskey, E., & Taylor, D. M. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.104 · Cited by 16
Swenne, I., & Rosling, A. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0098 · Cited by 16
Clozapine induced pancytopenia leading to severe sepsis: an unusual early complication
Pushpakumara, J., Karunarathna, P. G. P. S., Sivathiran, S., Liyanage, A., & Indrakumar, J. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1777-5 · Cited by 16
Rapidly developing and self‐limiting eosinophilia associated with clozapine
Wysokiński, A., & Kolińska, J. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12208 · Cited by 15
Fatal agranulocytosis: The use of olanzapine in a patient with schizophrenia and myelodysplasia
Stip, É., Langlois, R., Thuot, C., & Mancini-Marïe, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.08.005 · Cited by 13
Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies
Alalawi, A. M., Albalawi, E., Aljohani, A., Almutairi, A., Alrehili, A., Albalawi, A., & Aldhafiri, A. J. (2024) · Pharmacy · doi:10.3390/pharmacy12030092 · Cited by 11
Safety of a Clozapine Trial Following Quetiapine-Induced Leukopenia: A Case Report
Almaghrebi, A. H. (2018) · Current Drug Safety · doi:10.2174/1574886313666180807094654 · Cited by 11
Lin, A., Forsyth, J. K., Hoftman, G. D., Kushan, L., Jalbrzikowski, M., Dokuru, D. R., Coppola, G., Fiksinski, A., Zinkstok, J., Vorstman, J. A. S., et al. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100386 · Cited by 11
Late Onset Neutropenia Associated With Clozapine
Raja, M., Azzoni, A., & Maisto, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318234eec2 · Cited by 11
Severe Neutropenia and Agranulocytosis
Lally, J., & Flanagan, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803376-0.00005-8 · Cited by 11
Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series
Nakamura, M., & Nagamine, T. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000311 · Cited by 11
Filia, S., Lee, S. J., Sinclair, K., Wheelhouse, A., Wilkins, S., de Castella, A. R., & Kulkarni, J. (2013) · Australasian Psychiatry · doi:10.1177/1039856213498427 · Cited by 10
Evaluación del paciente con trombocitopenia
Maya, G. C. (2007) · Medicina y Laboratorio · Cited by 10
A granulocytosis associated with rufinamide: A case report
Ide, M., Kato, T., Nakata, M., Saito, K., Yoshida, T., Awaya, T., & Heike, T. (2015) · Brain and Development · doi:10.1016/j.braindev.2014.12.010 · Cited by 9
Practical considerations for carbamazepine use in bipolar disorder
Fuller, M. A., Dostrow, V., Gupta, S., & Gazda, T. D. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.501 · Cited by 9
Tinospora cordifolia attenuates antipsychotic drug induced hyperprolactinemia in Wistar rats
Tiwari, P. K., Dubey, S. K., & Sahu, P. K. (2019) · Asian Pacific Journal of Reproduction · doi:10.4103/2305-0500.259171 · Cited by 8
Management of Systemic Medical Emergencies Associated with Psychotropic Medications
Grover, S., Sarkar, S., & Avasthi, A. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_1014_21 · Cited by 8
Thrombocytopenia and Spontaneous Intracranial Hemorrhage After Olanzapine Therapy
Cruz, M. D., & Danoff, R. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.092 · Cited by 8
Dorney, K., & Murphy, M. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12980 · Cited by 8
Clinical preference for factors in treatment of geriatric depression
Riepe, M. W. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75450 · Cited by 7
A Case of Chronic Drug-Induced Neutropenia
Khan, A. Y., Golewale, M. H., & Kahn, D. A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000327316.27023.5d · Cited by 7
Sahnoun, D., Ghanmi, A., Gazzeh, S., Saguem, B. N., Slim, R., Nakhli, J., & Salem, C. B. (2024) · Pharmacopsychiatry · doi:10.1055/a-2262-8297 · Cited by 6
Lurasidone associated neutropenia
Singh, S. P., Ahmad, H., & John, A. P. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417708869 · Cited by 6
Thinn, S. S., Liew, E., May, A. L., Chua, H. C., & Sim, K. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000264987.70850.6a · Cited by 6
Aripiprazole-Induced Neutropenia in a Seven Year-Old Male: A Case Report
Majeed, M. H., & Ali, A. A. (2017) · Cureus · doi:10.7759/cureus.1561 · Cited by 5
Iachina, M., Ljungdalh, P. S., Sørensen, R. G., Kærlev, L., Blaakær, J., Trosko, O., Qvist, N., & Nørgård, B. M. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.11.006 · Cited by 5
Is prolonged stem cell mobilization detrimental for hematopoiesis?
Chigaev, A., Winter, S. S., & Sklar, L. A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.09.015 · Cited by 5
Aripiprazole induced leucopenia and neutropenia – case series
Kumar, P., Azeez, L. A., Gopalakrishnan, A., & Uvais, N. A. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113408 · Cited by 4
Kontrolluntersuchungen unter Therapie mit Psychopharmaka
Stuppäck, C., Geretsegger, C., & Egger, C. (2010) · Springer eBooks · doi:10.1007/978-3-211-85473-0_12 · Cited by 4
Hypereosinophilia Associated With Risperidone in a Drug-Naive Patient: A Case Report
Shukla, A., & Aggarwal, S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001100 · Cited by 3
Pharmacotherapy in Prader-Willi Syndrome
Forster, J. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98171-6_22 · Cited by 3
Msigwa, V., Morawej, Z., Kinyaga, A., Matovelo, S. A., & Nyundo, A. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06491-2 · Cited by 3
Hematologiczne działania niepożądane leków psychotropowych — wskazówki dla lekarza praktyka
Pawełczyk, T., Pawełczyk, A. M., & Rabe‐Jabłońska, J. (2011) · Psychiatria · Cited by 3
Pharmacogenomic screening for agranulocytosis and efficacy with clozapine
Shad, M. U. (2023) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2023.11 · Cited by 3
Chigaev, A., Sklar, L. A., Schrader, R., Stephens, N., Raissy, H., & Winter, S. S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.448 · Cited by 3
Jombo, H. E., & Ekwere, T. A. (2018) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2018/40894 · Cited by 3
Zabel, L., Ersek, N., Hofmann, A. B., Machetanz, L., Kirchebner, J., & Stübner, S. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/3858403 · Cited by 2
Self-citationCrohn's Disease Mimicking Bulimia Nervosa
Borum, M. L., & Liu, E. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0510c · Cited by 2
Ruiz-Fernández, C., Akatbach-Bousaid, I., Rogozina, O., Martín-López, S., Álvarez-Montero, M., Puras, R. P., Moreno, Z. D. S., Lopez, F. C. D., Urroz, M., Martínez‐Feito, A., et al. (2025) · Diagnosis · doi:10.1515/dx-2025-0077 · Cited by 2
The Relief of Leukocytopenia Within 1 Month After Switching Risperidone to Amisulpride
Hou, Y., & Lai, C. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13070162 · Cited by 2
Campion, P., Campion, G. H., & Anbarasan, D. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000733 · Cited by 2
Evaluation of potential drug-drug interactions in psychiatric patients: a pilot study
Zhelyazkova-Savova, M., Todorova-Nenova, K., Gancheva, S., & Karadjova, D. (2018) · Scripta Scientifica Medica · doi:10.14748/ssm.v50i3.5484 · Cited by 2
Chadwick, H. M., & Bressington, D. T. (2009) · Wiley eBooks · doi:10.1002/9781444316155.ch2 · Cited by 2
Agranulocytosis with combination of paliperidone and clozapine: a case report
Dehanov, S., Santos, M. J., Gonçalves, P., & Correia, T. M. (2020) · Clinical Neuropsychopharmacology and Therapeutics · doi:10.5234/cnpt.11.79 · Cited by 2
Bupropion-induced leukopenia: A case report (eng)
Gürcan, G., & Gürcan, A. (2021) · Journal of Clinical Psychiatry · doi:10.5505/kpd.2021.02419 · Cited by 2
Schmidt, R. H. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/1272 · Cited by 2
Haloperidol Decanoate-Induced Pancytopenia: A Case Report
Jagtiani, A., Veigne, S., Gandhi, R., & Rizvi, A. (2023) · Cureus · doi:10.7759/cureus.47402 · Cited by 1
Annamalai, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-51026-2_28 · Cited by 1
Nøytropeni ved behandling med antipsykotika
Torp, H. A., & Nystøyl, B. (2020) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.19.0713 · Cited by 1
Shakya, S., Shrestha, S., Pandey, S. R., Adhikari, B., Joshi, D., Shrestha, S., Bhandari, S., Yadav, S. K., & Lama, A. (2022) · F1000Research · doi:10.12688/f1000research.109997.1 · Cited by 1
Annamalai, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-51026-2_26 · Cited by 1
Optimización del uso deantipsicóticos en esquizofrenia
DíazPires, A., Aldana, I. G., Macías-Valcayo, A., & RuizDíaz, J. (2014) · Library Open Repository (Universidad Complutense Madrid) · Cited by 1
Oloyede, E., Alcaraz, J. M. L., Whiskey, E., Dzahini, O., Joyce, D. W., Shergill, S. S., Strodthoff, N., Taylor, D. M., & Bachmann, C. (2025) · medRxiv · doi:10.1101/2025.03.07.25323575 · Cited by 1
Carvajal, A., Arias, L. H. M., & Bulnes, N. J. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29006-8
Drs. Ghaznavi and Bhagwagar Reply
Ghaznavi, S., & Bhagwagar, Z. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071105r
Introduction to Blood Cell Disorders
Annamalai, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-51026-2_25
Shin, J.-H., Oh, S.-M., Kim, W., Bae, J. N., Lee, J.-S., Kim, C. E., & Kim, J. (2017) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2017.20.2.61
Kelly, J. P. (2009) · Wiley eBooks · doi:10.1002/9780470682920.ch7
Eosinofilia inducida por Olanzapina: A propósito de un caso.
Javiera Domazos, M., Tomás Serón, D., & Felipe Echeverría, P. (2020) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272020000100061
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg014
Inclusions bodies in blood dyscrasias: A diagnostic aid
Arora, K. S., Joshi, S., Gautam, S., & Sankhyan, N. (2022) · Journal of Oral Medicine Oral Surgery Oral Pathology and Oral Radiology · doi:10.18231/j.jooo.2022.001
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01137-9
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53266-4.50005-7
Annamalai, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-51026-2_30
Saldanha, M. J., & Zschornack, M. V. (2023) · Research Society and Development · doi:10.33448/rsd-v12i6.41872
Chopra, A., & Kantipudi, S. J. (2025) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_213_24
Metadata
- Authors
- Stübner, S., Grohmann, R., Engel, R. R., Bandelow, B., Ludwig, W.-D., Wagner, G., Müller-Oerlinghausen, B., Möller, H. ‐., Hippius, H., & Rüther, E.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Göttingen (DE)
- Humboldt-Universität zu Berlin (DE)
- Arzneimittelkommission der deutschen Ärzteschaft (DE)
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-03
- Volume
- 37
- Pages
- 70-78
- ISSN
- 0176-3679 (ISSN-L)
- 0936-9528
- 1439-0795
- OpenAlex
- W2404606726
- Cited by
- 100
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 11 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 2
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
- Keywords
- drug-induced blood dyscrasias, psychotropic drugs, neutropenia, thrombocytopenia, agranulocytosis, pancytopenia, clozapine, carbamazepine, perazine, olanzapine, risperidone, atypical antipsychotics, antidepressants, pharmacovigilance, risk estimation
- MeSH terms
- Adult, Age Factors, Aged, Cell Count, Dose-Response Relationship, Drug, Drug Interactions, Female, Follow-Up Studies, Glucose Tolerance Test, Hematologic Diseases, Humans, Leukocytes, Male, Middle Aged, Neutropenia, Product Surveillance, Postmarketing, Psychotic Disorders, Psychotropic Drugs, Retrospective Studies, Sex Factors, Time Factors, Incidence, Confidence Intervals, Drug Monitoring, Adverse Drug Reaction Reporting Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.